2,2,2-三氟乙基氯甲酸酯 | 27746-99-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 2,2,2-三氟乙基氯甲酸酯
• 英文名称: 2,2,2-trifluoroethyl chloroformate
• 英文别名: 2,2,2-trifluoroethyl carbonochloridate；2,2,2-trifluoroethoxycarbonyl chloride
• CAS: 27746-99-2
• 化学式: C₃H₂ClF₃O₂
• mdl: MFCD00800932
• 分子量: 162.496
• InChiKey: UJZBSAONPRVEIJ-UHFFFAOYSA-N

物化性质

• 沸点：
  40 °C(Press: 165 Torr)
• 密度：
  1.4896 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R23/24/25,R34
• 危险品运输编号：
  UN 3277
• 海关编码：
  2915900090
• 包装等级：
  II
• 危险类别：
  6.1,8
• 危险性防范说明：
  P210,P240,P241,P242,P243,P260,P264,P271,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P370+P378,P403+P233,P403+P235,P405,P501
• 危险性描述：
  H226,H314,H331
• 储存条件：
  | 室温 |

反应信息

• 作为反应物：
  描述：

  2,2,2-三氟乙基氯甲酸酯 在 sodium peroxide 作用下， 反应 2.0h， 以75%的产率得到di(2,2,2-trifluoroethyl)peroxydicarbonate
  参考文献：
  名称：

  Synthesis and properties of di(polyfluoroalkyl) peroxydicarbonates

  摘要：

  Synthesis of di(polyfluoroalkyl)peroxydicarbonates [X(CF(2)) (n) CH(2)OC(O)O](2), where X = H, F; n = 1, 2, 4, 6 (yield 80%) involves the step of the chloroformate formation (yield up to 93%) via the phosgenation of polyfluorinated alcohols followed by the reaction with sodium peroxide. The rate constant of monomolecular decomposition k (term) was found to decrease as the polyfluoroalkyl groups were incorporated into the peroxide: it equaled 3.30 and 3.10 s(-1) for X = H, n = 2 and 4, respectively, and 7.36 s(-1) for di-n-butylperoxydicarbonate. The new peroxides are a source of the polyfluoroalkoxy radicals and nano-modifiers of the polymers to improve their heat resistance and light stability.

  DOI：

  10.1134/s1070363211050100
• 作为产物：
  描述：

  2,2,2-Trifluoroethyl ethylsulfanylformate 在 磺酰氯 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 2,2,2-三氟乙基氯甲酸酯
  参考文献：
  名称：

  O-Chlorocarbonylation of β-Nitroalcohols and 2,2,2-Trihaloethanols viaO-AlkylS-Ethyl Thiocarbonates

  摘要：

  DOI：

  10.1055/s-1979-28774

文献信息

• APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20200157095A1

  公开（公告）日：2020-05-21

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明公开了化合物的结构式(I)，以及其药学上可接受的盐和酯： 这些化合物抑制凋亡信号调节激酶1（ASK-1），与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾脏疾病、心血管疾病相关。本发明还涉及包含上述化合物的药物组合物，用于治疗患有ASK-1相关疾病的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的ASK-1相关疾病的方法。本发明具体涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎病（NASH）。
• [EN] SPIROCYCLIC INDOLINES AS IL-17 MODULATORS<br/>[FR] INDOLINES SPIROCYCLIQUES UTILISÉES COMME MODULATEURS D'IL-17
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2018229079A1

  公开（公告）日：2018-12-20

  A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

  一系列替代的螺环式2-氧吲哚衍生物及其类似物，作为强效的人IL-17活性调节剂，因此在治疗和/或预防各种人类疾病，包括炎症性和自身免疫性疾病方面具有益处。
• Nonpeptidic inhibitors of human leukocyte elastase. 5. Design, synthesis, and x-ray crystallography of a series of orally active 5-aminopyrimidin-6-one-containing trifluoromethyl ketones
  作者：Chris A. Veale、Peter R. Bernstein、Craig Bryant、Christopher Ceccarelli、James R. Jr. Damewood、Roger Earley、Scott W. Feeney、Bruce Gomes、Ben J. Kosmider

  DOI：10.1021/jm00001a015

  日期：1995.1

  activity and oral activity in an acute hemorrhagic assay have been explored. These compounds contained either a trifluoromethyl ketone or a boronic acid moiety to bind covalently to the Ser-195 hydroxyl of human leukocyte elastase (HLE). Boronic acid-containing inhibitors were found to be more potent than the corresponding trifluoromethyl ketones in vitro but were less active upon oral administration

  已经探索了一系列5-氨基-2-嘧啶-6-酮的取代变化对急性出血试验中体外活性和口服活性的影响。这些化合物包含三氟甲基酮或硼酸部分，以与人白细胞弹性蛋白酶（HLE）的Ser-195羟基共价结合。发现含硼酸的抑制剂在体外比相应的三氟甲基酮更有效，但是口服给药时活性较低。发现化合物13b提供了口服效力，作用持续时间和酶选择性的最佳组合，因此，选择了其用于进一步的生物学测试。
• [EN] AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS<br/>[FR] AMINOPYRROLOTRIAZINES EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019147782A1

  公开（公告）日：2019-08-01

  The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

  该公开涉及到公式I的化合物，这些化合物可用作激酶调节剂，包括RIPK1调节。该公开还提供了制备和使用这些化合物的方法，例如在涉及坏死或炎症以及其他适应症的治疗中使用。
• [EN] TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES DE QUINOLÉINE ET D'AZAQUINOLINE À SUBSTITUTION HÉTÉROARYLE INHIBITEURS DE PAR4
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018013776A1

  公开（公告）日：2018-01-18

  Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

  揭示了化合物的结构式（I）至（VIII）：（I）（II）（III）（IV）（V）（VI）（VII）（VIII）或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中R3是一个三环杂芳基，其上取代有R3a和零至2个R3b；R1、R2、R3a、R3b、R4和n在此有定义。还揭示了将这些化合物用作PAR4抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在抑制或预防血小板聚集方面很有用，并且可用于治疗血栓栓塞性疾病或血栓栓塞性疾病的初级预防。